Metabolic & Weight Management
VK2735
Last updated
Evidence on file6 randomised human trials · 4 citations not yet graded
Strongest sourceWeekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13… (randomised human trial)
Dosing on file unverified
Titrate to 15 mg/week
Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.
Literature on file 10
-
human RCT
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. graded on: a randomised study — “Randomized, 13-Week VENTURE Study”
-
human RCT
NCT07104383: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight graded on: randomised and placebo-controlled — “Randomized, Double-Blind, Placebo-Controlled”
-
human RCT
NCT07104500: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition graded on: randomised and placebo-controlled — “Randomized, Double-Blind, Placebo-Controlled”
-
human RCT
NCT06068946: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition graded on: randomised and placebo-controlled — “Randomized, Double-Blind, Placebo-Controlled”
-
human RCT
NCT06828055: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition graded on: randomised and placebo-controlled — “Randomized, Double-Blind, Placebo-Controlled”
-
human RCT
NCT05203237: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index graded on: randomised and placebo-controlled — “Randomized, Double-Blind, Placebo-Controlled”
Not graded
4 citations whose study design could not be read from the title. Left ungraded rather than guessed at.
- not graded
- not graded
- not graded
- not graded
Notes unverified prose
Phase 2; (VENTURE); Phase 3 VANQUISH
Not on file 8
8 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.
- molecular weightnothing we hold supplies it
- molecular formulanothing we hold supplies it
- CAS registry numbernothing we hold supplies it
- PubChem identifiernothing we hold supplies it
- amino-acid sequencenothing we hold supplies it
- SMILES stringnothing we hold supplies it
- InChInothing we hold supplies it
- InChI keynothing we hold supplies it
Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.